Mersen S.A. (EPA:MRN) Half-Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Shareholders might have noticed that Mersen S.A. (EPA:MRN) filed its half-year result this time last week. The early response was not positive, with shares down 3.4% to €31.50 in the past week. It was an okay report, and revenues came in at €624m, approximately in line with analyst estimates leading up to the results announcement. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Mersen after the latest results.

View our latest analysis for Mersen

earnings-and-revenue-growth
ENXTPA:MRN Earnings and Revenue Growth August 2nd 2024

Taking into account the latest results, the current consensus from Mersen's seven analysts is for revenues of €1.28b in 2024. This would reflect a credible 3.9% increase on its revenue over the past 12 months. Before this earnings report, the analysts had been forecasting revenues of €1.27b and earnings per share (EPS) of €3.57 in 2024. Overall, while the analysts have reconfirmed their revenue estimates, the consensus now no longer provides an EPS estimate. This implies that the market believes revenue is more important after these latest results.

There's been no real change to the consensus price target of €49.86, with Mersen seemingly executing in line with expectations. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Mersen, with the most bullish analyst valuing it at €54.00 and the most bearish at €45.00 per share. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Mersen'shistorical trends, as the 8.0% annualised revenue growth to the end of 2024 is roughly in line with the 7.9% annual growth over the past five years. Juxtapose this against our data, which suggests that other companies (with analyst coverage) in the industry are forecast to see their revenues grow 6.5% per year. It's clear that while Mersen's revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself.

Advertisement

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their revenue estimates for next year, suggesting that the business is performing in line with expectations. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

We have estimates for Mersen from its seven analysts out to 2026, and you can see them free on our platform here.

You should always think about risks though. Case in point, we've spotted 1 warning sign for Mersen you should be aware of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ENXTPA:MRN

Mersen

Manufactures and sells electrical power products and advanced materials in France, North America, rest of Europe, the Asia-Pacific, and internationally.

Excellent balance sheet with slight risk.

Advertisement

Weekly Picks

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5360.5% undervalued
135 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
DE
Degen_GCR
P logo
Degen_GCR on Everpure ·

Second order memory play likely to double in a year

Fair Value:US$18053.1% undervalued
18 users have followed this narrative
1 users have commented on this narrative
12 users have liked this narrative
DO
Double_Bubbler
LUNR logo
Double_Bubbler on Intuitive Machines ·

Intuitive Machines: To The Moon and Beyond!

Fair Value:US$42.315.7% undervalued
9 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
YI
APP logo
yiannisz on AppLovin ·

AppLovin’s AI Engine Is Printing Profit

Fair Value:US$989.2454.2% undervalued
30 users have followed this narrative
2 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

KA
kapirey
UNCY logo
kapirey on Unicycive Therapeutics ·

Unicycive Therapeutics is a late-stage clinical biotech transitioning toward commercialization

Fair Value:US$9.177.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kapirey
1364 logo
kapirey on Guming Holdings ·

A scaled, high-growth, franchise-driven beverage leader with strong penetration in China

Fair Value:HK$47.5650.7% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
HE
HedgeY
IONQ logo
HedgeY on IonQ ·

The Best-Funded Quantum Platform and Still a Stock Priced for Perfection

Fair Value:US$4815.1% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8589.8% undervalued
108 users have followed this narrative
2 users have commented on this narrative
31 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.226.0% undervalued
70 users have followed this narrative
2 users have commented on this narrative
24 users have liked this narrative
TR
tripledub
META logo
tripledub on Meta Platforms ·

The $135 Billion Bet That Should Make Every Shareholder Nervous

Fair Value:US$74016.7% undervalued
36 users have followed this narrative
3 users have commented on this narrative
33 users have liked this narrative